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Synthesis of 4-nitrosalicylanilide derivatives with potential antibacterial activity 
Diploma thesis 
Charles University in Prague, Faculty of Pharmacy in Hradec Kralove 
Pharmacy 
 
Background: The point of this diploma work was the synthesis of 4-
nitrosalicylanilide derivatives, as a possible antibacterial agents against 
Mycobacterium tuberculosis. 
Methods: All reactions were monitored, and the purity of products was verified 
by TLC in which the plates were coated with silica gel 60 F254. They were also 
visualized using UV irradiation, while the column chromatography, was 
performed using silica gel 60. 
 The melting points of products were determined on a Melting Point 
apparatus and Büchi are uncorrected, IR spectra were recorded using ATR 
technique and the NMR spectra were measured in DMSO-d6 or CDCl3.  
Results: The reactions between the starting compounds were successfully 
proceeded under the microwave reactor and the presence of chlorobenzene, 
trimethylamine and phosphorus trichloride. 
Conclusion: Unfortunately some of the final products of these experiments 
were probably triethylamine salts of salicylanilides that was determined on 
NMR spectra. 
. 





Syntéza4-nitrosalicylanilidových derivátů s potenciálníantibakteriálníaktivitou 
Diplomovápráce 
Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové 
 
Cíl: Cílem této diplomové práce byla syntéza několika 4-nitrosalicylanilidových 
derivátů s potenciální antibakteriální aktivitou. 
Metody: Čistota produktů a průběh reakcí byly sledovány chromatografií na 
tenké vrstvě na hliníkových deskách firmy Merck potažených silikagelem 
60F254 zavizualizace UV zářením. Chromatografické čištění na koloně bylo 
provedeno na silikagelu 60.  
 Teploty tání připravených sloučenin byly měřeny na bodotávku Büchi a 
jsou uvedeny bez korekce, IČ spektrabyla měřena technikou ART a NMR 
spektra byla měřena v CDCI3 nebo DMSO-d6. 
Výsledky: Kondenzační reakce byly prováděny v mikrovlnném reaktoru. 
Výchozí sloučeniny se ponechaly reagovat v chlorbenzenu za přítomnosti 
trimethylaminu a chloridu fosforitého. 
Závěr: Některé připravené salicylanilidy jsou patrně ve formě 
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DOTS   Directly observed treatment short-course  
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1. Introduction –Tuberculosis and Its Treatment 
 
1.1 History of Tuberculosis 
Speaking about the history of Tuberculosis (TB), it is actually believed 
in ourdays that has been present in humans’ lives for some thousands of 
years. According to previous foundings, skeletal remains can show that some 
prehistoric humans (4.000 BC) appraise to have tuberculosis, and tubercular 
decay has been found in the spines of Egyptian mummies (3.000-2.400 BC)1.  
 
It is also a fact that during the 17th century, specific exact pathological 
and anatomical descriptions of tuberculosis, began actually to appear. In 
about 1679, Sylvius proceeded to write his Opera Medica, in which he was 
then the first to identify the actual tubercles as also a consistent and for the 
characteristic change in the lungs and other areas of all the consumptive 
patients. The earliest references to the infectious nature of tuberculosis also 
appeared in 17th century Italian medical literature2. 
 
It was also a fact that due to the variety of the symptoms existed, 
tuberculosis was not identified like an unified disease until the decade of 
1820s and was not actually named tuberculosis until year 1839, by J.L. 
Schonlein. Due to existence of tuberculosis that year, it was in 1854, when 
Hermann Brehmer proposed actually the idea that tuberculosis was 
mentioned indeed as a curable disease2. In advance, the introduction of the 
sanatorium cure provided actually the first big step toward treatment for 
tuberculosis. Brehmer was also a TB patient. His doctor was the one who 
advised him to proceed to a healthier environment and climate, so he spent 
some time in the Himalayas and came home cured. This specific experience 
moved him so as to build the first sanatorium, a place where patients could 
get plenty of fresh air and good nutrition. This setup mentioned as the 
blueprint for the subsequent development of sanatoriums accordingly1.  
 
It should also be said that the measures available to doctors at the time 
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were still modest, although there was a feeling for development in treatment 
of patients3. By trying to improve any social and sanitary conditions as also to 
proceed by ensuring some adequate nutrition, there were all that could be 
done to strengthen the body's defenses against TB bacteria in those days. 
Sanatoriums, in our days, found throughout Europe and the United States, 
provided a dual function. They isolated the sick, actually the source of the 
infection from the general population where they forced the patients to rest, 
actually assisting the healing process. 
 
Although the fact that the development of sanatoriums helped in 
providing a haven for those healing from tuberculosis, there were scientists 
and doctors who continued their research in the hopes of finding a real cure 
for the disease. Several techniques of the tuberculosis treatment were 
discovered, including actually methods3: 
  
 Artificial pneumothorax 
 Radiation 
 Chemotherapy.   
 
Those methods are analyzed as follows3: 
 
 Artificial Pneumothorax - Forlanini, who was an Italian physician, 
discovered actually that lung collapse had actually a positive effect on 
the outcome of the mentioned disease. Upon the introduction of the 
artificial pneumothorax and surgical techniques so as to reduce the 
lung volume, the active therapy for tuberculosis began. Although this 
was mentioned as an accomplished technique, it was discontinued 
after 1946 because it proved some little benefits. 
 Radiation - Some further significant advances came up actually in 1895 
by the time that Wilhelm Konrad von Roentgen discovered the radiation 
that bears his name. With this discovery, it was now possible to follow 
and accurately review the progress and severity of a patient's disease. 
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 Chemotherapy – Concerning the method of chemotherapy in TB, it is 
actually a fact that in the middle of the World War II, this additional 
breakthrough was discovered. The administering chemotherapy to 
some other infectious disease, making use of sulphonamide and 
penicillin, this had already been underway for several years. Although, 
these molecules turned out to be ineffective against Mycobacterium 
tuberculosis. 
  
But except from the above, doctors and specialists proceeded by 
making use of antibiotics as treatment for TB. This is mentioned to the year of 
1943, where Selman A. Waksman, had been working for decades so as to 
find a specific antibiotic that could be effective against the Mycobacterium 
tuberculosis4. The medicine of streptomycin purified from Streptomyces 
griseus that was first administered to a human on November 20, 1944. The 
results were also appeared to be extremely impressive. The disease 
immediately stopped its progression, the bacteria disappeared from the 
patient's sputum, and he was then recovered fully. 
 
It is also mentioned that a rapid succession of anti-TB drugs was also 
appeared during the following years. This was something very important due 
to the fact that upon the streptomycin treatment, resistant mutants began 
actually to appear within a few months, endangering the success of antibiotic 
therapy. However, it was soon proven that using a combination of drugs 
would solve this problem1. 
 
But since then and despite all the drugs available today, tuberculosis is 
still considered to be a problem in various nations. According to World Health 
Organization (WHO), it is estimated that each year, about eight millions of 
people worldwide could develop some active tuberculosis and close to two 
million die, unfortunately4. Although the overall rate of the new tuberculosis 
cases has actually continued to decline in the United States since national 
reporting began in 1953, the annual decrease in tuberculosis cases appeared 
to have slowed dramatically. TB still continues to kill between two and three 
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millions people every year. The WHO estimates also that thirty six (36) million 
people will die of the tuberculosis by 2020 if this could be not controlled. 
 
Another fact that actually plays an important role in development of TB 
since our days, is that mentioned that the registered number of new cases of 
TB worldwide could roughly be correlated upon the economic conditions. It 
has been found that the highest incidences are found in these countries of 
Africa, Asia, and Latin America comprising the lowest gross national products. 
According to the above, the World Health Organization estimates actually that 
nine million people get TB every year, of whom 95% live in developing 
countries. An estimated 2-3 million people die from TB every year5. 
It should also be noted that the industrialized countries, the steady drop 
in TB incidence started to level off in the mid-1980s and then stagnated or 
even started to increase accordingly. Much of this rise could also be at least 
partially attributed to a high rate of immigration from countries with a high 
incidence of TB. It is also important that a great influence in the rising TB 
trend is concerned to HIV infection. Appropriate chances are that only one out 
of ten immune-competent people infected with M. tuberculosis will fall sick in 
their lifetimes with active TB, but among those with HIV, one in ten per year 
will develop active TB, while one in two or three tuberculin test positive AIDS 
patients will develop active TB26. In some industrialized countries, this is 
mentioned as a tragedy for the patients involved, but it these cases make up 
only a small minority of TB cases. In developing countries, the impact of HIV 
infection on the TB situation, especially in the 20-35 year age group, is of 
great and increasing concern. 
It has also to be said that one final factor which contributes to the 
resurgence of TB that is the emergence of multi-drug resistance. The drug 
resistance in the TB occurs therefore, as a result of tubercle bacillus 
mutations. These mutations are not dependent upon the presence of the 
drug17. Exposed to a case of single effective anti-TB medication, the aspect of 
predominant bacilli, sensitive to that drug, are killed; the few drug resistant 
mutants, likely to be present if the bacterial population is large, will, multiply 
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freely. Since it is very unlikely that a single bacillus will spontaneously mutate 
to resistance to more than one drug, giving multiple effective drugs 
simultaneously will inhibit the multiplication of these resistant mutants. This is 
why it is absolutely essential to treat TB patients with the recommended four-
drug regimen of isoniazid, rifampin, pyrazinamide, and ethambutol or 
streptomycin5. 
Finally it is actually mentioned that although there is a number of 
wealthy industrialized countries upon good public health care systems that 
can be expected so as to keep TB under control, in some of the developing 
world a catastrophe awaits. It is also important that support could be given to 
research efforts devoted to developing an effective TB vaccine, shortening 
actually the amount demanded for the time required so as to ascertain drug 
sensitivities, improving also the diagnosis of TB and creating by far some 
new, highly effective anti-TB medications. Without any support for such 
efforts, people run the risk of losing the battle against TB5. 
 
 
1.2 Pathophysiology of Tuberculosis 
 
 
Mentioned to the pathophysiology of Tuberculosis (TB) in ourdays, it 
has actually been mentioned that sometimes is concerned to be under 
recognized; People start first upon the way of how they would be able to 
obtain a definitive diagnosis of tuberculosis. In such cases, it is mentioned 
that tuberculosis has actually reemerged as a major health concern in recent 
years3.  
Only in the United States, it has been noted that approximately 14.000 
cases of tuberculosis were reported in 2011, a 3.2% decline from the previous 
year of 2010 although, about 20 states and the District of Columbia had 
higher rates of TB1. It is also mentioned that the prevalence of tuberculosis is 
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continuing to increase because of the increased number of patients infected 
with human immunodeficiency virus, bacterial resistance to medications, 
increased international travel and immigration from countries with high 
prevalence, and the growing numbers of the homeless and drug abusers3.  
It is also a fact that the vulnerability of the hospitalized patients to the 
disease of tuberculosis is often concerned to be under recognized due to the 
infection which is habitually considered a disease of the community 
accordingly. Most hospitalized patients are in a suboptimal immune state, 
particularly in intensive care units, making exposure to tuberculosis even 
more serious than in the community. By understanding of the causative 
organism, pathophysiology, transmission, and diagnostics of tuberculosis and 
the clinical manifestations in patients, critical care are better prepared to 
recognize infection, prevent transmission, and treat this increasingly common 
disease2. 
Tuberculosis is mentioned as an infection caused by the rod-shaped, 
non–spore-forming, aerobic bacterium Mycobacterium tuberculosis3. It is 
provided that mycobacteria typically measure 0.5 μm by 3 μm, are classified 
as acid-fast bacilli, and have a unique cell wall structure crucial to their 
survival. The well-developed cell wall contains a considerable amount of a 
fatty acid, mycolic acid, covalently attached to the underlying peptidoglycan-
bound polysaccharide arabinogalactan, providing an extraordinary lipid 
barrier.  
This specific barrier is concerned to be responsible for a number of the 
medically challenging physiological characteristics of tuberculosis, including 
resistance to antibiotics and host defense mechanisms7. The composition and 
quantity of the cell wall components affect the bacteria’s virulence and growth 
rate5. It is a fact that the peptidoglycan polymer can confer cell wall rigidity 
and it is just external to the bacterial cell membrane, another contributor to the 
permeability barrier of mycobacteria. In advance, an important component of 
the cell wall is mentioned the lipoarabinomannan, a carbohydrate structural 
antigen on the outside of the organism that is immunogenic and facilitates the 
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survival of mycobacteria within macrophages4. As to the cell wall, this is 
mentioned as the key to the survival of mycobacteria, and a more complete 
understanding of the biosynthetic pathways and gene functions and the 
development of antibiotics to prevent formation of the cell wall are areas of 
great interest5. 
Based on the above, it is also mentioned that once inhaled, the 
infectious droplets can settle throughout the airways. The majority of the 
bacilli are trapped in the upper parts of the airways where the mucus-
secreting goblet cells exist5. Then the mucus produced, it can catch some 
foreign substances as the cilia on the surface of the cells can beat the mucus 
and its entrapped particles upward for removal4. This specific system provides 
the body with an initial physical defense that prevents infection in most 
persons exposed to tuberculosis2. 
It is also noticed that the bacteria mentioned in droplets that bypass the 
mucociliary system and reach the alveoli, they are quickly surrounded and 
engulfed by alveolar macrophages, the most abundant immune effector cells 
present in alveolar spaces1. Those macrophages, the next line of host 
defense, are actually part of the innate immune system and provide an 
opportunity for the body to destroy the invading mycobacteria and prevent 
infection5.  
The macrophages are readily available to phagocytic cells which could 
combat many pathogens without requiring previous exposure to the 
pathogens. Various mechanisms and macrophage receptors are also involved 
in the uptake of the mycobacteria4. This mycobacterial lipoarabinomannan is 
mentioned as a key ligand for a macrophage receptor. The complement 
system also plays a role in the phagocytosis of the bacteria. It is also 
mentioned that the complement protein C3 binds to the cell wall and 
enhances recognition of the mycobacteria by macrophages. The procedure of 
opsonization by C3 is rapid, even in the air spaces of a host with no previous 
exposure to M. tuberculosis3. It is also a fact that the subsequent 
phagocytosis by macrophages initiates a cascade of events that results in 
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either successful control of the infection, followed by latent tuberculosis, or 
progression to active disease, called primary progressive tuberculosis21. The 
outcome is mentioned essentially to be determined by the quality of the host 
defenses and the balance that occurs between host defenses and the 
invading mycobacteria8. 
In the next stage and after being ingested by macrophages, the 
mycobacteria continue to multiply slowly, with bacterial cell division occurring 
every 25 to 32 hours5. Regardless of the fact if the infection can become 
controlled or progresses, any initial development can involve the production of 
proteolytic enzymes and cytokines by macrophages in an attempt to degrade 
the bacteria4. The released cytokines can attract the T lymphocytes to the site 
where the cells that constitute cell-mediated immunity.  
For those patients upon intact cell-mediated immunity, the next 
defensive step is formation of granulomas around the M. tuberculosis 
organisms5. These nodular-type lesions form from an accumulation of 
activated T lymphocytes and macrophages, which creates a micro-
environment that limits replication and the spread of the mycobacteria5. This 
environment destroys macrophages and produces early solid necrosis at the 
centre of the lesion; however, the bacilli are able to adapt to survive. 
It is actually a fact that M. tuberculosis organisms can also change their 
phenotypic expression, like the protein regulation so as to enhance survival2. 
By 2 or 3 weeks, the characterized as necrotic environment resembles soft 
cheese, often referred to caseous necrosis, and is characterized by low 
oxygen levels, low pH, and limited nutrients. This specific condition restricts 
further growth and establishes latency. In advance some lesions in persons 
with an adequate immune system generally undergo fibrosis and calcification, 
successfully controlling the infection so that the bacilli are contained in the 
dormant, healed lesions5. Those lesions in persons with less effective immune 
systems progress to primary progressive tuberculosis1. 
Finally it should be said that for less immunocompetent persons, 
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granuloma formation is initiated yet ultimately is unsuccessful in containing 
the bacilli4. It is also a fact that the necrotic tissue undergoes liquefaction, and 
the fibrous wall loses structural integrity. The semiliquid necrotic material can 
then drain into a bronchus or nearby blood vessel, leaving an air-filled cavity 
at the original site. In patients infected with M. tuberculosis, droplets can be 
coughed up from the bronchus and infect other persons. If any discharge into 
a vessel occurs, then occurrence of extrapulmonary tuberculosis is likely to 
happen5. Bacilli can also drain into the lymphatic system and collect in the 
tracheobronchial lymph nodes of the affected lung, where the organisms can 
form new caseous granulomas3. 
1.3 Appropriate Drugs for Tuberculosis in Nowadays 
 




Rifampicin is an antibiotic used to treat infections, including 
tuberculosis. It is usually prescribed as one of a number of medicines to treat 
the infection. You may have been prescribed it for this reason. Alternatively, 
you may have been prescribed it to protect you from a serious infection 
caused by certain bacteria. Rifampicin works by stopping the bacteria causing 
the infection from growing and multiplying2. 
Tuberculosis is a bacterial infection which is mostly found in the lungs 
but which can affect any part of your body. TB is treatable with a course of 
medicines which usually last six months. Several medicines are given 
together to treat TB. There are some brands of tablets available which contain 







Isoniazid is used to treat tuberculosis or prevent its return 
(reactivation). It may be given alone, or in combination with other medicines, 
to treat TB or to prevent its return (reactivation). This medicine may also be 
used for other problems as determined by patients doctor1. This medicine 
may cause some serious side effects, including damage to the liver. Liver 
damage is more likely to occur in patients over 50 years of age. Patients and 
their doctor should talk about the good this medicine will do, as well as the 
risks of taking it3. 
If patients are being treated for active tuberculosis (TB): To help clear 
up patients’ TB infection completely, they must keep taking this medicine for 
the full time of treatment, even if patients begin to feel better. This is very 
important. It is also important that they do not miss any doses. Isoniazid is 
available only with patients’ doctor's prescription. This product is available in 







Ethambutol is an antibiotic that is used to treat tuberculosis. It works by 
stopping the bacteria that cause this disease from growing and increasing in 
numbers. There are two stages in the treatment for tuberculosis. In the first 
two months treatment is aimed at killing as many bacteria as possible9. 
Therefore several anti-TB drugs with different mechanisms of action are used 
at the same time (usually rifampicin, pyrazinamide, isoniazid and ethambutol). 
After this time some of the medicines are stopped and the others (usually 
rifampicin and isoniazid) are continued for a further four months to kill any 
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remaining bacteria. Ethambutol is used in the initial phase of treatment only2.  
 
The bacteria that cause TB are difficult to treat. By using several 
medicines at the same time, the bacteria can be targeted in different ways 
and hence treatment is more likely to be effective than using a single 
medicine. In addition, using different medicines together makes it less likely 
that bacteria will develop resistance to the treatment. Ethambutol tablets are 
usually taken once daily with or without food. The tablets should be swallowed 
with a drink of water. Take ethambutol exactly as directed. Patients should 




Pyrazinamide (PZA) is an antimicrobial agent that is most commonly 
used for treatment of active tuberculosis during the initial phase of therapy 
(generally the first two months of treatment), in combination with other agents. 
The spectrum of PZA is relatively narrow; it demonstrates clinically significant 
antibacterial activity only against Mycobacterium tuberculosis and M. 
africanum5. Issues related to the clinical use of pyrazinamide will be reviewed 
here. Issues related to treatment of latent and active TB are discussed 
separately. 
The parent compound is metabolized via pyrazinamidase (PZase) to 
pyrazinoic acid; pyrazinoic acid is the active form of the drug4. The 
mechanism of action for PZA is not known. PZA and its analog, 5-chloro-PZA, 
may inhibit the fatty acid synthetase I (FASI) enzyme of M. tuberculosis3. PZA 
is generally considered to be a bacteriostatic agent. 
PZA thought to be more active at an acidic pH (eg, within 
macrophages) and against dormant or semidormant microorganisms, 
although the role of PZA against intracellular organisms remains uncertain. In 
one study, pyrazinoic acid remained outside of M. tuberculosis cells at a 
neutral or alkaline pH but accumulated within cells at an acidic pH. In the 
same study, M. smegmatis (which is not susceptible to PZA) was found to 
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convert PZA to pyrazinoic acid but due to an active efflux mechanism did to 
accumulate the metabolite, even at an acidic pH. Other mycobacterial strains 
appear to have natural resistance to PZA due to lack of PZase activity or 
absence of transport mechanisms to take up the drug2. 
When used as part of combination therapy, PZA appears to accelerate the 
sterilizing effect of isoniazid and rifampin5. In selected populations this has 
enabled reduction in the duration of treatment infection due to susceptible M. 




Streptomycin is an aminocyclitol-aminoglycoside antibiotic produced by 
Streptomyces griseus. Streptomycin consists of aminocyclitol (streptidine), 6-
deoxyhexose (streptose), and N-methyl-L-glucosamine moieties, which are 
formed by independent biosynthetic pathways. All of the moieties are derived 
from D-glucose. The streptidine moiety is synthesized via myo-inositol, which 
is then oxidized at C-1 and transaminated to give scyllo-inosamine. After 
phosphorylation, the compound is transaminated by arginine. The same 
procedure is repeated at the C-3 position. The streptose moiety is made from 
D-glucose via a dTDP-glucose pathway. The exact biosynthetic route for the 
N-methyl-L-glucosamine moiety is unknown, though the biosynthetic gene 
cluster has been proposed3. 
 
The four mainstream first-line drugs for treating active tuberculosis as 
mentioned above, are isoniazid (INH), rifampicin (RIF), ethambutol (EMB), 
and pyrazinamide (PZA). The combination of these four anti-tuberculosis 
drugs constitutes the basis of the directly observed treatment short-course 
(DOTS) strategy internationally recommended by WHO to treat smear positive 
TB patients infected with drug-susceptible strains of M. tuberculosis. The 
DOTS strategy was developed in order to limit the development of drug-




A proper management of the DOTS strategy consists of administration 
of INH, RIF, EMB, and PZA for two months, followed by the use of INH and 
RIF for an additional four months for a total duration of six months. During the 
two first months, in some countries and in some situations, EMB is sometime 
substituted by streptomycin, which is considered a first-line TB drug as well, 
but not preferred when EMB is available. Application of the DOTS strategy is 
effective even in cases when TB patients are infected with strains of M. 
tuberculosis resistant to one of the four mainstream TB drugs8. 
1.3.2 Drugs of 2nd Line  
 
Ciprofloxacin is used to treat or prevent certain infections caused by 
bacteria. Ciprofloxacin is also used to treat or prevent anthrax (a serious 
infection that may be spread on purpose as part of a bioterror attack) in 
people who may have been exposed to anthrax germs in the air. Ciprofloxacin 
extended-release (long-acting) tablets are used only to treat certain types of 
urinary tract infections. Ciprofloxacin is in a class of antibiotics called 
fluoroquinolones. It works by killing bacteria that cause infections. Antibiotics 
will not work for colds, flu, or other viral infections4. 
Ciprofloxacin comes as a tablet, a suspension (liquid), and an 
extended-release tablet to take by mouth. The tablet and suspension are 
usually taken twice a day, in the morning and evening, with or without food. 
The extended-release tablets are usually taken once a day. Cipro XR brand 
extended-release tablets may be taken with or without food.  
Proquin XR brand extended-release tablets should be taken with a 
main meal of the day, preferably the evening meal. Take ciprofloxacin at 
around the same time(s) every day. The length of your treatment depends on 
the type of infection you have. Patients’ doctor will tell them how long to take 
ciprofloxacin. They should follow the directions on their prescription label 
carefully, and ask their doctor or pharmacist to explain any part they do not 
understand. They have to take ciprofloxacin exactly as directed. They should 




One brand or type of ciprofloxacin cannot be substituted for another. 
They have to be sure that they receive only the brand or type of ciprofloxacin 
that was prescribed by their doctor. They also should not take ciprofloxacin 
with dairy products or calcium-fortified juices alone. However, they may take 
ciprofloxacin with a meal that includes these foods or drinks. They should 
swallow the tablets whole; do not split, crush, or chew them. If they cannot 
swallow tablets whole, tell their doctor. 
If patients are taking the suspension, they should shake the bottle very 
well for 15 seconds before each use to mix the medication evenly. They 
should swallow the correct dose without chewing the granules in the 
suspension. They have to close the bottle completely after each use. Do not 
give the suspension to a patient through a feeding tube. Lastly they should 
begin feeling better during the first few days of their treatment with 
ciprofloxacin. If their symptoms do not improve or if they get worse, they have 
to call their doctor. If they are being treated for a urinary tract infection, they 
have to call their doctor if patients develop fever or back pain during or after 




Clarithromycin is used to treat certain types of bacterial infections. It 
works by killing certain types of bacteria. Other information about 
Clarithromycin3: 
 
 This medicine is a powder. Water will be added to the medicine to 
make it into a liquid for patients to take. This is usually done by the 
pharmacy at the time of dispensing. Dispose of the made-up solution 
14 days after the day that water was added. It is a good idea to 
make a note of the date that water was added so you will know when 
to dispose of Clarithromycin 
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 They do not share their medicine with other people. It may not be 
suitable for them and may harm them. 
 The pharmacy label on their medicine tells patients how much 
medicine they should take. It also tells them how often they should take 
their medicine. This is the dose that patients and their prescriber have 
agreed they should take. They should not change the dose of their 
medicine unless patients are told to do so by their prescriber. 
 If patients feel that the medicine is making their unwell or they do not 
think it is working, then talk to their prescriber. 
 Clarithromycin is not suitable for everyone and some people should 
never use it. Other people should only use it with special care. It is 
important that the person prescribing this medicine knows their full 
medical history. 
 
Their prescriber may only prescribe this medicine with special care or 
may not prescribe it at all if patients4: 
 
 are allergic or sensitive to or have had a bad reaction to macrolides 
in the past 
 are allergic or sensitive to or have had a reaction to any of the 
ingredients in the medicine 
 have a slow heart rate 
 have kidney problems 
 have metabolic problems 
 have myasthenia gravis 
 have or have had heart problems 
 have or have had liver problems 
 
Furthermore the prescriber may only prescribe this medicine with 
special care or may not prescribe it at all for a child under the age of six 
months or weighs less than eight Kg. As part of the process of assessing 
suitability to take this medicine a prescriber may also arrange tests to 
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determine whether or not the medicine is suitable and whether it must be 
prescribed with extra care1. Over time it is possible that Clarithromycin can 
become unsuitable for some people, or they may become unsuitable for it. If 
at any time it appears that Clarithromycin has become unsuitable, it is 





Cycloserine is an antibiotic that is used to treat tuberculosis (TB)10. It 
works by killing the bacteria that cause this disease. Cycloserine stops the 
tuberculosis bacteria from making cell walls correctly. The cell walls of 
bacteria are vital for their survival. They keep unwanted substances from 
entering their cells and stop the contents of their cells from leaking out. By 
weakening their cell walls, cycloserine kills the bacteria. Tuberculosis bacteria 
are difficult to eliminate and can become resistant to the medicines that are 
used to treat this infection. Cycloserine is used when the bacteria have 
become resistant to other medicines that are usually prescribed to treat TB. 
 
Cycloserine will be given in combination with other medications that 
target the bacteria in different ways. This helps to make it more difficult for the 
bacteria to develop resistance to the medicines. It is used for the following 
cases1: 
 
  Treatment of tuberculosis that is resistant to first-line medicines 
(isoniazid, rifampicin, pyrazinamide, streptomycin and ethambutol), or 
when these medicines cause unacceptable side effects. Cycloserine is 
used in combination with other anti-tuberculous medicines. 
  Cycloserine capsules should be swallowed with a drink of water. 
They can be taken either with or without food. 
  Cycloserine capsules are usually taken twice a day (morning 
and evening, every 12 hours). The number of capsules to take will vary 
from person to person. It is important to follow the instructions given by 
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their doctor. These will also be printed on the dispensing label that your 
pharmacist has put on the packet of medicine. 
  Patients have to try to always take their doses at the same 
times. This will help them remember to take them. 
  If patients forget to take a dose, take it as soon as they 
remember, unless it is almost time to take their next dose. In this case, 
they should skip the missed dose and take their next dose when it is 
due.  





Capreomycin is an injectable broad-spectrum antibiotic used in the 
therapy of drug-resistant tuberculosis as a second line agent, always in 
combination with other ant tuberculosis drugs10. Capreomycin has not been 
linked to cases of clinically apparent liver disease4. Capreomycin is a 
polypeptide antibiotic initially isolated from the bacterium, Streptomyces 
capreolus. Capreomycin is believed to act by binding to bacterial ribosomes 
and inhibiting protein synthesis. Capreomycin is similar to viomycin and is 
considered bacterostatic rather than bacterocidal. While structurally different, 
capreomycin has similar antibacterial activity and side effects to the 
aminoglycosides (streptomycin, kanamycin, amikacin)2. 
   
Capreomycin is currently used only as a secondary agent in the 
treatment of active tuberculosis, always in combination with other 
antituberculosis agents such as isoniazid, ethambutol, pyrazinamide and/or 
rifampin (but not streptomycin or the aminoglycosides) and usually for multi-
drug resistant mycobacterial infections. Capreomycin was approved for use in 
the United States in 1973 but is currently rarely used, streptomycin or a 
modern aminoglycoside being used in its place. Capreomycin is available in 
vials for intramuscular or intravenous injection under the trade name of 
Capastat. The typical dose is 15 mg/kg/day (maximum of 1 gram per day) 
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intramuscularly for 2 to 4 months. The dose must be modified based upon 
renal function5. 
 
Intramuscular therapy with capreomycin has not been definitely linked 
to liver injury, either in the form of asymptomatic elevations in serum enzymes 
or of clinically apparent liver injury. However, the agent is rarely used and is 
always used in combination with other antituberculosis medications, many of 
which are well known to cause liver injury. Nevertheless, in the few studies 
done, capreomycin has not been associated with an increase in the rate of 
serum enzyme elevations or in episodes of acute liver injury above or beyond 
what was reported in the comparator arm1. 
 
Capreomycin is excreted largely unchanged in the urine. Its lack of 
hepatic metabolism and known renal toxicity may account for its lack of 
hepatotoxicity. The majority of toxicities of capreomycin resemble those of 
streptomycin and the aminoglycosides and includes oto- and nephrotoxicity5. 
First line medications used in the therapy of tuberculosis in the United States 
include isoniazid, pyrazinamide, ethambutol and the rifamycins including 
rifampin, rifabutin and rifapentine. Second line medications include 
streptomycin, capreomycin, cycloserine, ethionamide, fluoroquinolones such 
as levofloxacin, and moxifloxacin, aminoglycosides such as amikacin and 
para-aminosalicylic acid (PAS)1. 
 
  It should also be mentioned that while the DOTS strategy has shown to 
be effective at curing TB cases and limiting the occurrence of drug-resistant 
M. tuberculosis strains in countries where the program is rigorously managed, 
nevertheless, cases of drug-resistant TB are still recorded. Conventionally, M. 
tuberculosis strains that are resistant to at least INH and RIF are termed 
multidrug resistant M. tuberculosis (MDR-TB)8.  
 
Anti-tuberculosis compounds used to treat MDR-TB cases are called 
second line anti-tuberculosis drugs. They are also commonly used to treat 
immune-compromised patients such as HIV patients who are infected with 
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atypical mycobacterial species. Though effective against M. tuberculosis at 
different degrees, second line TB drugs have the disadvantage of exhibiting 
relatively strong side effects in comparison with their first-line drugs 
counterparts8.  
 
Treatment of MDR-TB strains is more complex and requires 
characterization of strains in order to adapt the treatment to each patient. In 
MDR-TB cases, a 24-month regimen is usually recommended with the use of 
one or several second-line drugs. The TB pandemic is even more complex 
today because of emergence of M. tuberculosis strains resistant to not only 
first-line anti-tuberculosis drugs, but also to some second-line drugs. These 
TB strains resistant to both first-line and second-line drugs are named 
extensively drug-resistant tuberculosis (XDR-TB). 
 
Aminoglycosides are able to be used in treating MDR-TB comprise 
kanamycin and its derivative, amikacin. Both kanamycin and amikacin are 
administered parenterally11. Capreomycin, another injectable second-line anti-
tuberculosis drug is a macrocyclic polypeptide agent used to treat MDR-TB 
patients. It has a different chemical structure from that of kanamycin and 
amikacin, but share with these two aminoglycosides, the same mechanism of 
action, leading to the conclusion that acquisition of resistance to one drug 
may also cause a cross-resistance to other drugs8.  
 
Nevertheless, this phenomenon could also be extremely variable from 
one strain to another. In spite of its bacteriostatic activity on M. tuberculosis, 
D-cycloserine has not been very much used in traditional TB treatment 
because of its neurotoxic effects on TB patients. It is only used in combination 
with other drugs in case of MDR-TB infection. D-cycloserine is a structural 
analog of D-alanine, an essential amino acid in bacterial cell wall synthesis. 
Several fluoroquinolones exhibits an anti-mycobacterial activity in vitro, but 
only a small fraction including ciprofloxacin, levofloxacin, ofloxacin, and 




Ciprofloxacin and ofloxacin have been used with success against TB 
cases recently12, but the emergence of drug resistance casting doubt as to 
whether fluoroquinolones should be used in TB treatment. What is more, 
fluoroquinolones affect the growth of M.tuberculosis by targeting gyrA and 
gyrB, two genes encoding DNA gyrases. Resistance to fluoroquinolones is 
caused by mutations in mycobacterial genes gyrA and gyrB, para-
aminosalicylic acid (PAS) was introduced as TB treatment option by the end 
of 1940s8.  
 
PAS was extensively used worldwide in the treatment of TB until about 
2000 despite gastric side effects. Treatment of TB using PAS requires 
relatively large doses of drug because of its high level of excretion. PAS has a 
bacteriostatic effect of M. tuberculosis4. Today, PAS tends to be used for 
treating MDR-TB patients (Peloquin) as better drugs exist to treat susceptible 
M. tuberculosis strains. Thioamides compounds including ethionamide (ETH) 
and prothionamide are recommended and in fact very commonly used in the 
treatment of MDR-TB cases. Although the specific mechanisms of action of 
thioamides compounds have not been fully elucidated, these antituberculosis 
drugs appear to inhibit synthesis of mycolic acids8. 
 
1.4 Role of Salicylates in Tuberculosis 
 
Salicylate is a ubiquitous molecule that is involved in systemic acquired 
disease resistance in plants13. Salicylate is the active component of aspirin, 
which is one of the most popular medicines used in the prevention and 
treatment of a wide variety of disease conditions. During the analysis of the 
effect of organic acids on the oxidative metabolism of the tubercle bacillus in 
the 1940s, Bernheim found that salicylate increased the oxygen consumption 
of the bacilli, whereas structurally related benzoic acid had a much weaker 
effect13.  
Based on this observation, Lehmann and colleagues identified the 
salicylate analogue p-aminosalicylic acid (PAS) as an effective 
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antituberculosis (anti-TB) agent (now used as a second-line TB drug)5, even 
though the mode of action of PAS is probably not directly related to the effect 
of salicylate on tubercle bacilli. 
Salicylates were first described to induce a multiple antibiotic 
resistance (Mar) phenotype in Escherichia coli13, and it is now known to 
induce antibiotic resistance in a variety of bacterial species13. In the E. 
coli system, salicylate induces antibiotic resistance by binding to MarR and 
activating the transcription of marA and marB. MarA and MarB regulate a 
range of genes that confer a Mar phenotype, including down-regulation of 
OmpF porin expression via micFantisense RNA to limit the entry of 
antibiotics13 and switching on of efflux pumps such as AcrAB to more 
effectively extrude antibiotics from the cells13.  
However, salicylate also induces antibiotic resistance through a Mar-
independent pathway, since a Mar deletion strain still showed resistance in 
the presence of salicylate13. In gram-positive bacteria such as Staphylococcus 
aureus, salicylate induces resistance to antibiotics such as fluoroquinolone, 
although the mechanism involved is unknown. One possible mechanism is 
that M. tuberculosis may have a Mar-like regulatory mechanism as in E. coli.  
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Over expression of the E. coli marA on a multicopy plasmid in the fast 
growing organism M. smegmatis mediates resistance to multiple 
antimycobacterial agents, indicating the presence of amar-like regulatory 
system in this organism13. However, MarA over expression was not performed 
with M. tuberculosis in that study. A MarA homolog (Rv1931) is present in 
the M. tuberculosis genome; however, the degree of homology of Rv1931 to 
MarA is quite low.  
Preliminary studies showed that the Rv1931 mRNA was not induced by 
salicylate (data not shown), indicating that Rv1931 is unlikely to be 
responsible for the salicylate-induced drug resistance in M. tuberculosis. On 
the other hand, salicylate may reduce the permeability of the mycobacterial 
cell membrane as a mechanism for the salicylate induced drug resistance 
in M. tuberculosis.  
A preliminary study using C14-INH has suggested that the uptake of 
INH by M. tuberculosis H37Ra is reduced in the presence of salicylate (data 
not shown). The possibility of an involvement of efflux pumps in salicylate-
induced resistance in M. tuberculosis remains to be tested. Further studies 
are needed to determine the precise mechanism of the salicylate-induced 
drug resistance in M. tuberculosis. Because salicylate is widely used in the 
prevention and treatment of diverse disease conditions at concentrations (up 
to 2 μM)13 that are known to induce resistance to various drugs in M. 
tuberculosis in vitro, it will be of interest to assess the effect of salicylate on 










2. Experimental part 
The aim of the thesis 
General methods 
 The reactions were monitored, and the purity of products was verified 
by thin layer chromatography in which the plates were coated with 0.2 mm 
silica gel 60 F254 (Merck, Prague, Czech Republic) and visualized using UV 
irradiation (254 and 366 nm). Column chromatography was performed using 
silica gel 60 with a particle size of 0.063-0.2 mm (Fluka, Prague, Czech 
Republic).  
 The melting points of products were determined on a Melting Point B-
540 apparatus (Bűchi Labortechnik AG, Flawil, Switzerland) in open 
capillaries and are uncorrected. IR spectra were recorded on a Nicolet 6700 
FT-IR spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) over the 
range of 400-4000 cm-1 using ATR technique. The NMR spectra were 
measured in DMSO-d6 or CDCl3 solutions at ambient temperature on a Varian 
Mercury Vxbb 300 (300 MHz for 1H and 75.5 MHz for 13C, Varian Comp. Palo 
Alto, CA, USA) and Varian Mercury (500 MHz for 1H and 125 MHz for 13C, 



















 Substituted salicylic acid (0.01mol) was dissolved in 50 ml of 
chlorobenzene, 0.01 mol of substituted aniline was added. The mixture was 
stirred 10 minutes and after that 0.435 ml (0,005 mol) of PCl3 was added drop 
by drop. 
 The reaction mixture was boiled under the reflux condenser in the 
microwave reactor for 20 minutes at 120 oC at 450 W.  
















Chemical Formula: C13H9N3O6                          





 1.8437  g of 2-hydroxy-4-nitrobenzoic acid 
 1.3928 g of 4-nitroaniline 
 50 ml of chlorobenzene 
 0.435 ml of PCl3  
 1.2 ml of triethylamine 
 
Procedure: 
 The mixture of the above contents was boiled in the microwave reactor 
at 120 oC and 400 watt for 20 minutes. After that, 30 ml of NaHCO3 were 
added in order to form precipitation and this precipitate was filtrated. 
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 This precipitate, which was named St 1(1), was recrystallized five 
times to obtain the final product. 
Weight of product : 0.1169 gr 
m.p. :250-256 oC 
 
1H NMR (500 MHz, DMSO) δ 13.03 (1H, bs, NH), 7.93 (1H, d overlapped, 
J=8.6 Hz, H6), 7.93-7.89 (2H, m, AA´, BB´, H3´, H5´), 7.70-7.65 (2H, m, AA´, 
BB´, H2´, H6´), 7.50 (1H, d, J=2.4 Hz, H3), 7.36 (1H, dd, J=8.6 Hz, J=2.4 Hz, 
H5)  
IR ν (CONH-) : 1681 cm-1 




Compound was found in the database Reaxys, without any characteristics, 









Chemical Formula: C13H9N3O6 




 1.8391  g of 2-hydroxy-4-nitrobenzoic acid 
 1.3806 g of 3-nitroaniline 
 50 ml of chlorobenzene 
 0.435 ml of PCl3  
 1.2 ml of triethylamine 
Procedure: 
 The mixture of the above contents was boiled in the microwave reactor 
at 120 oC and 400 watt for 20 minutes. After that, 30 ml of NaHCO3 were 
added in order to form precipitation and this precipitate was filtrated. 
 This precipitate, which was named St 2(1), was mixed with diluted HCl (5ml 
of concentrated HCl +10 ml of distilled H2O) and let it stirred for 15 minutes. 
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 Then, it was filtered off and washed with distilled water. In addition, 5 ml of 
NaHCO3  and small amount of water were used  in order to wash away the 
impurities of the solution. 
 Finally, it was dried, recrystallized and filtered off twice to obtain the product. 
Weight of product : 0.5083 gr 
m.p. :222-224 oC 
% yield= 3.61% 
1H NMR (300 MHz, DMSO) δ 11.69 (1H, bs, NH), 10.84 (1H, bs, OH), 8.76 
(1H, t, J=2.1 Hz,  H2´), 8.08-7.94 (2H, m, H4´, H6´), 7.91 (1H, d, J=8.2 Hz, 
H6), 7.77 (1H, d, J=2.1 Hz, H3), 7.76 (1H, dd, J=8.2 Hz, J=2.1 Hz, H5), 7.65 
(1H, t, J=8.2 Hz, H5´)  
13C NMR (75 MHz, DMSO) δ 164.6, 156.7, 149.8, 148.2, 138.7, 131.1, 130.4, 
127.4, 126.3, 118.8, 114.4, 113.9, 111.4 











Chemical Formula: C14H8F3N3O6 




 1.8318  g of 2-hydroxy-4-nitrobenzoic acid 
 2.0742 g of 3-trifluoromethyl-4-nitroaniline 
 50 ml of chlorobenzene 
 0.435 ml of PCl3  
 1.2 ml of triethylamine 
 
Procedure: 
 The mixture of the above contents was boiled in the microwave reactor 
at 120 oC and 400 watt for 20 minutes. After that, 30 ml of NaHCO3 were 
added in order to form precipitation and this precipitate was filtrated. 
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  This precipitate, named St 3(1), was mixed with ethylacetate until 
completely dissolved and filtrated. 
  The filtrate was evaporated till dryness and then recrystallized in 
ethanol twice to obtain the final product. 
Weight of product : 0.4446 g 
m.p. :231-234 oC 
% yield= 15.79% 
1H NMR (500 MHz, DMSO) δ 13.73 (1H, bs), 8.43 (1H, d, J=2.0 Hz,  H2´), 
8.19 (1H, d, J=8.8 Hz, H5´), 8.06 (1H, dd, J=8.8 Hz, J=2.0 Hz, H6´), 7.89 (1H, 
d, J=8.3 Hz, H6), 7.47 (1H, d, J=2.4 Hz, H3), 7.35 (1H, dd, J=8.3 Hz, J=2.4 
Hz, H5)  
13C NMR (125 MHz, DMSO) δ 165.8, 164.0, 150.5, 144.4, 141.3, 131.0, 
127.9, 125.2, 123.3 (q, J=32.4 Hz), 122.3 (q, J=272.8 Hz), 121.2, 118.0 (q, 
J=6.7 Hz), 113.5, 108.7 











Chemical Formula: C14H9F3N2O4 




 1.8379 g of 2-hydroxy-4-nitrobenzoic acid 
 1.6160 g of 4-trifluoromethylaniline 
 50 ml of chlorobenzene 
 0.435 ml of PCl3  
 1.2 ml of triethylamine 
 
Procedure: 
 The mixture of the above contents was boiled in the microwave reactor 
at 120 oC and 400 watt for 20 minutes. After that, 25 ml of NaHCO3 were 
added in order to form precipitation and this precipitate was filtrated. 
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 This precipitate that was collected from this filtration was recrystallized 
in ethanol and filtrated to obtain the final product. 
 
Weight of product : 1.3608 gr 
m.p. : 219-220 oC 
% yield= 45.39% 
1H NMR (300 MHz, DMSO) δ 13.03 (1H, bs, NH), 7.93 (1H, d overlapped, 
J=8.8 Hz,  H6), 7.95-7.88 (2H, m, H3´, H5´), 7.72-7.65 (2H, m, H2´, H6´), 7.50 
(1H, d, J=2.2 Hz, H3), 7.36 (1H, dd, J=8.8 Hz, J=2.2 Hz, H5)  
13C NMR (75 MHz, DMSO) δ 165.0, 163.9, 150.3, 143.0, 131.0, 126.3 (q, 
J=3.5 Hz), 125.6, 124.6 (q, J=271.8 Hz), 123.4 (q, J=32.3 Hz), 119.9, 113.4, 
108.6 
IR ν (CONH-) : 1670 cm-1 











Chemical Formula: C14H9F3N2O4 




 1.8364 g of 2-hydroxy-4-nitrobenzoic acid 
 1.6230 g of 3-trifluoromethylaniline 
 50 ml of chlorobenzene 
 0.435 ml of PCl3  
 1.2 ml of triethylamine 
 
Procedure: 
 The mixture of the above contents was boiled in the microwave reactor 
at 120 oC and 400 watt for 20 minutes. After that, 20 ml of NaHCO3 were 
added in order to form precipitation and filtered off.  
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 The product of this filtration was recrystallized with ethanol three times 
to obtain the final one. 
 
Weight of product : 1.1738 gr 
m.p. : 190.5-191.5 oC 
% yield= 33.93% 
1H NMR (500 MHz, DMSO) δ 13.01 (1H, bs, NH), 8.28 (1H, bs, H2´), 7.93 
(1H, d, J=8.2 Hz, H4´), 7.81 (1H, d, J=8.8 Hz, H6), 7.56 (1H, t, J=8.2 Hz, H5´), 
7.50 (1H, d, J=2.2 Hz, H3), 7.43-7.39 (1H, m, H6´), 7.36 (1H, dd, J=8.8 Hz, 
J=2.2 Hz, H5) 
13C NMR (125 MHz, DMSO) δ 165.1, 163.9, 150.3, 140.2, 131.0, 130.2, 129.8 
(q, J=31.4 Hz), 125.6, 124.4 (q, J=271.8 Hz), 123.5, 119.7 (q, J=3.9 Hz), 
116.0 (q, J=3.9 Hz), 113.4, 108.6 











Chemical Formula: C14H8Cl2F3NO2 




 1.8302 g of 2-hydroxy-4-nitrobenzoic acid 
 1.7740 g of 3,4-dichloroaniline 
 50 ml of chlorobenzene 
 0.435 ml of PCl3  
 1.2 ml of triethylamine 
 
Procedure: 
 The mixture of the above contents was boiled in the microwave reactor 
at 120 oC and 400 watt for 20 minutes. After that, 30 ml of NaHCO3 were 
added in order to form precipitation and this precipitate was filtrated. 
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 This precipitate, named as St 6(1), was mixed with enough amount  of 
ethylacetate to get completely dissolved and filtrated. 
  This filtrate was evaporated till dryness and then recrystallized twice to 
obtain the final product. 
 
Weight of product : 0.1160 gr 
m.p. :222-224 oC 
% yield= 3.22 % 
 
1H NMR (500 MHz, DMSO) δ 12.98 (1H, bs, NH), 8.16 (1H, bs, H2´), 7.90 
(1H, d, J=8.5 Hz, H6), 7.58-7.51 (2H, m, H5´, H6´), 7.48 (1H, d, J=2.3 Hz, 
H3), 7.35 (1H, dd, J=8.5 Hz, J=2.3 Hz, H5)  
13C NMR (125 MHz, DMSO) δ 164.9, 163.8, 150.3, 139.5, 131.3, 130.9, 
130.9, 125.4, 124.8, 121.1, 120.0, 113.4, 108.6 












Chemical Formula: C14H8F3N3O6 




 2.2839 g of 2-hydroxy-3,5-dinitrobenzoic acid 
 1.6283 g of 3-trifluoromethyl-aniline 
 50 ml of chlorobenzene 
 0.435 ml of PCl3  
 1.3 ml of triethylamine 
 
Procedure: 
 The mixture of the above contents was boiled in the microwave reactor 
at 120 oC and 400 watt for 20 minutes. After that, 25 ml of NaHCO3 were 
added in order to form precipitation and this precipitate was filtrated. 
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 The filtrate was separated and the chlorobenzene layer (lower part) 
was kept. In this solution HCl was added and two layers appeared, which 
were separated again. 
 From this separation the lower phase was evaporated till dryness and 
ethylacetate was added. Then, it was separated, recrystallized and filtrated. 
 At the same time, the precipitation collected from the first filtration, 
named as St7(1), was recrystallized and filtrated twice. 
 Unfortunately, the amount of product from both experimental ways was 






















Chemical Formula: C14H8F3N3O6 




 2.2836  g of 2-hydroxy-3.5-dinitrobenzoic acid 
 1.6120 g of 4-trifluoromethyl-aniline 
 50 ml of chlorobenzene 
 0.435 ml of PCl3  
 1.2 ml of triethylamine 
 
Procedure: 
 The mixture of the above contents was boiled in the microwave reactor 
at 120 oC and 400 watt for 20 minutes. After that, 30 ml of NaHCO3 were 
added in order to form precipitation and this precipitate was filtrated. 
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 The filtrate was separated and the chlorobenzene layer (lower part) 
was kept. In this solution HCl was added and two layers appeared, which 
were separated again. 
 From this separation the lower phase was evaporated till dryness and 
hexane was added. Then, it was evaporated again and ethylacetate was 
added. This solution was evaporated, recrystallized and filtrated. 
 At the same time, the precipitation collected from the first filtration, 
named as St8(1), was recrystallized and filtrated twice. 
 Unfortunately, the amount of product from both experimental ways was 

















3. Conclusion  
 
 According to the results of the NMR measurement some products 
seem to be triethylammonium salts of salicylanilides. This fact was found in 
the end of my experimental part. On TLC prepared compounds showed only 
one running spot, thus we expected pure product. Triethylamine was used to 
catch up hydrogen chloride which is formed during the reaction mechanism.. 
Phenolic hydroxyl group is probably more acidic in our nitroderivatives than in 
other earlier prepared salicylanilides, nitro group has strong electron acceptor 
effect and thus increases acidity.  
 The expected results from the tests, which took place in Ostrava 
University, unfortunately are not available at the moment, due to the problems 
we confronted during the period of our experimental work.  
 Finally , these results, whose tests are still in progress, will revile the 
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